| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-06-27 | mepolizumab | severe bilateral nasal polyps | 3 | GSK (UK) | Inflammatory diseases |
| 2017-06-27 | GKT831 (formerly GKT137831) | primary biliary cholangitis (PBC) | 2 | Genkyotex (Switzerland) | Liver diseases - Hepatic diseases |
| 2017-06-27 | KL1333 | genetic mitochondrial diseases | 1 | Neurovive Pharmaceutical (Sweden) Yungjin Pharm (South Korea) | Rare diseases - Genetic diseases |
| 2017-06-26 | fitusiran (SAR439774 - ALN-AT3) | hemophilia A | preclinical | Alnylam Pharmaceuticals (USA - MA) | Hematological diseases - Genetic diseases - Rare diseases |
| 2017-06-26 | givosiran (ALN-AS1) | acute hepatic porphyria | observational | Alnylam Pharmaceuticals (USA - MA) | Rare diseases - Metabolic diseases |
| 2017-06-26 | ALN-F12 | hereditary angioedema, prevention of thrombosis | preclinical | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-06-26 | CB 2679d/ISU304 | hemophilia B | preclinical | Catalyst Biosciences (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-06-25 | CD44v6 CAR-T cells | preclinical | Molmed (Italy) | Cancer - Oncology | |
| 2017-06-24 | Idhifa® (enasidenib) | relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation | 1-2 | Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) | Cancer - Oncology |
| 2017-06-24 | AG-348 | pyruvate kinase deficiency | 2 | Agios Pharmaceuticals (USA -MA) | Rare diseases - Genetic diseases |
| 2017-06-23 | CTL019 - tisagenlecleucel-T | B-cell acute lymphoblastic leukemia | 2 | Novartis (Switzerland) | Cancer - Oncology |
| 2017-06-23 | Ocrevus® (ocrelizumab) | relapsing multiple sclerosis (RMS) primary progressive multiple sclerosis (PPMS) | 3 | Genentech, a member of Roche Group (USA - CA - Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2017-06-23 | Rydapt®(midostaurin) | newly diagnosed FLT3-mutated acute myeloid leukemia (AML) | 3 | Novartis (Switzerland) | Cancer - Oncology |
| 2017-06-22 | dasiglucagon (ZP4207) and bionic pancreas | type 1 diabetes | 2a | Zealand Pharma (Denmark) Beta Bionics (USA - MA) | Metabolic diseases |
| 2017-06-20 | IVA337 - lanifibranor- 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid) | NASH (non-alcoholic steatohepatitis) | preclinical | Inventiva Pharma (France) | Liver diseases - Hepatic diseases |
| 2017-06-19 | SGN-CD33A (vadastuximab talirine) in combination with azacitidine (Vidaza®) | myelodysplastic syndrome | 1-2 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-06-19 | vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine | acute myeloid leukemia | 3 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-06-17 | Truxima® (CT-P10 - biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) | advanced follicular lymphoma, rheumatoid arthritis | Celltrion Healthcare (South Korea) | Cancer - Oncology - Autoimmune diseases - Rheumatic diseases | |
| 2017-06-17 | MGD010 | autoimmune diseases | 1 | Macrogenics (USA - MD) | Autoimmune diseases |
| 2017-06-16 | ixekizumab | active psoriatic arthritis | 3 | Eli Lilly (USA - IN) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
